Long Term Follow-Up Study of a Randomized, Open-Label, Uncontrolled, Phase I/II Study to Assess the Safety and Immunogenicity of Intramuscular and Intradermal Doses of COVID-19 DNA Vaccine (AG0302-COVID19)

Overview

Journal Vaccines (Basel)

Date 2023 Oct 28

PMID 37896939

Authors

Hironori Nakagami

Tetsuya Matsumoto

Kenji Takazawa

Hisakuni Sekino

Osamu Matsuoka

Satoshi Inoue

Hidetoshi Furuie

Ryuichi Morishita

Affiliations

Soon will be listed here.

Abstract

Pharmacological studies have demonstrated antibody production and infection prevention with an intradermal coronavirus disease 2019 (COVID-19) DNA vaccine (AG0302-COVID-19). This clinical trial aimed to investigate the safety and immunogenicity of high doses of AG0302-COVID19 when injected intramuscularly and intradermally. Healthy adults were randomly divided into three intramuscular vaccination groups (2 mg, three times at 2-week intervals; 4 mg, twice at 4-week intervals; and 8 mg, twice at 4-week intervals) and two intradermal groups (1 mg, three times at 2-week intervals or twice at 4-week intervals). After a one-year follow-up, no serious adverse events were related to AG0302-COVID-19. At Week 52, the changes in the geometric mean titer (GMT) ratios of the anti-S antibodies were 2.5, 2.4, and 3.2 in the 2, 4, and 8 mg intramuscular groups, respectively, and 3.2 and 5.1 in the three times and twice injected intradermal groups, respectively. The number of INF-γ-producing cells responsive to S protein increased after the first dose and was sustained for several months. AG0302-COVID-19 showed an acceptable safety profile, but the induction of a humoral immune response was insufficient to justify progressing to a Phase 3 program.

References

Kraynyak K, Blackwood E, Agnes J, Tebas P, Giffear M, Amante D . SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial. J Infect Dis. 2022; 225(11):1923-1932. PMC: 8807286. DOI: 10.1093/infdis/jiac016. View

Porgador A, Irvine K, Iwasaki A, Barber B, Restifo N, Germain R . Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med. 1998; 188(6):1075-82. PMC: 2212529. DOI: 10.1084/jem.188.6.1075. View

Sullivan S, Doukas J, Hartikka J, Smith L, Rolland A . Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Deliv. 2010; 7(12):1433-46. DOI: 10.1517/17425247.2010.538047. View

Hengge U, Chan E, Foster R, Walker P, Vogel J . Cytokine gene expression in epidermis with biological effects following injection of naked DNA. Nat Genet. 1995; 10(2):161-6. DOI: 10.1038/ng0695-161. View

Nakagami H, Hayashi H, Sun J, Yanagida Y, Otera T, Nakagami F . Phase I Study to Assess the Safety and Immunogenicity of an Intradermal COVID-19 DNA Vaccine Administered Using a Pyro-Drive Jet Injector in Healthy Adults. Vaccines (Basel). 2022; 10(9). PMC: 9503587. DOI: 10.3390/vaccines10091427. View

Miyazaki H, Atobe S, Suzuki T, Iga H, Terai K . Development of Pyro-Drive Jet Injector With Controllable Jet Pressure. J Pharm Sci. 2019; 108(7):2415-2420. DOI: 10.1016/j.xphs.2019.02.021. View

Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K . DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med. 2011; 17(8):996-1002. DOI: 10.1038/nm.2403. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Haraguchi T, Koujin T, Shindo T, Bilir S, Osakada H, Nishimura K . Transfected plasmid DNA is incorporated into the nucleus via nuclear envelope reformation at telophase. Commun Biol. 2022; 5(1):78. PMC: 8776997. DOI: 10.1038/s42003-022-03021-8. View

10.

Khoury D, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8. View

11.

Sudowe S, Dominitzki S, Montermann E, Bros M, Grabbe S, Reske-Kunz A . Uptake and presentation of exogenous antigen and presentation of endogenously produced antigen by skin dendritic cells represent equivalent pathways for the priming of cellular immune responses following biolistic DNA immunization. Immunology. 2008; 128(1 Suppl):e193-205. PMC: 2753911. DOI: 10.1111/j.1365-2567.2008.02947.x. View

12.

Widera G, Austin M, Rabussay D, Goldbeck C, Barnett S, Chen M . Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol. 2000; 164(9):4635-40. DOI: 10.4049/jimmunol.164.9.4635. View

13.

Ahn J, Lee J, Suh Y, Song Y, Choi Y, Lee K . Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults. Lancet Microbe. 2022; 3(3):e173-e183. PMC: 8824525. DOI: 10.1016/S2666-5247(21)00358-X. View

14.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

15.

Bange E, Han N, Wileyto P, Kim J, Gouma S, Robinson J . CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021; 27(7):1280-1289. PMC: 8291091. DOI: 10.1038/s41591-021-01386-7. View

16.

Graham B, Enama M, Nason M, Gordon I, Peel S, Ledgerwood J . DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One. 2013; 8(4):e59340. PMC: 3620125. DOI: 10.1371/journal.pone.0059340. View

17.

Hayashi H, Sun J, Yanagida Y, Otera T, Kubota-Koketsu R, Shioda T . Preclinical study of a DNA vaccine targeting SARS-CoV-2. Curr Res Transl Med. 2022; 70(4):103348. PMC: 9020527. DOI: 10.1016/j.retram.2022.103348. View

18.

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020; 21(2):181-192. PMC: 7832443. DOI: 10.1016/S1473-3099(20)30843-4. View

19.

Felgner P . Improvements in cationic liposomes for in vivo gene transfer. Hum Gene Ther. 1996; 7(15):1791-3. DOI: 10.1089/hum.1996.7.15-1791. View

20.

Momin T, Kansagra K, Patel H, Sharma S, Sharma B, Patel J . Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine. 2021; 38:101020. PMC: 8285262. DOI: 10.1016/j.eclinm.2021.101020. View